Antipyretic TRIZ Cases

Blocking FcγRIIb binding helps CD20 antibodies avoid internalization, improve effector cell engagement, and enhance cancer cell deletion.

Epitope-specific anti-IFN-γ antibodies neutralize inflammatory signaling while preserving T-cell immunity and limiting off-target effects.

A single-domain albumin binder non-covalently associates with serum albumin to extend therapeutic half-life and improve pharmacokinetics.

High-affinity IL1RAP antibodies block IL-1, IL-33, and IL-36 signaling to address inflammatory, autoimmune, and proliferative diseases.

By blocking arginase in the tumor microenvironment, these compounds preserve L-arginine and restore anti-cancer immune cell function.

Boron-containing dual JAK and PDE4 modulators target inflammation with a distinct anti-inflammatory profile and potential for fewer adverse effects.

Specific anti-TL1A CDR sequences block IFN-γ, TNF-α, and apoptosis pathways to help treat IBD and intestinal fibrosis.

Blocking CD30L-CD30 signaling with humanized antibodies reduces immune activation and IL-6/IL-8 expression in Crohn's disease and ulcerative colitis.

pH-dependent anti-IL-8 antibodies neutralize IL-8 to reduce inflammation and adhesion in endometriosis while preserving fertility.

A methylcellulose-hyaluronan gel keeps local anesthetic at the injection site for over 48 hours while limiting systemic exposure and Cmax.

Selective small molecules inhibit TYK2 and JAK1 with sub-200 nM potency, enabling topical autoimmune and psoriasis treatment with fewer side effects.

Porous aragonite and calcite coral scaffolds balance mechanical support with cell ingrowth to repair bone and cartilage defects.

A histidine-sucrose-polysorbate 80 formulation keeps anti-IL-23p19 antibody stable at high concentration for subcutaneous delivery.

Targeting IL-4R with an antibody helps control CRSsNP more durably, lowers corticosteroid use, and reduces recurrence risk.

Human albumin and fibrinogen replace animal serum and added growth factors to form clinically safer MSC sheets with intact structure.

A topical cannabidiol blend with menthol and camphor delivers rapid, long-lasting pain relief while avoiding GI irritation and first-pass liver metabolism.

Cryoprotectant-free stem cell freezing with a blood substitute solution boosts IL-10 expression and preserves post-thaw efficacy for inflammatory and renal disease use.

Selective TL1A-binding antibodies use defined CDRs and Fc tuning to modulate inflammatory signaling with fewer side effects.

MRGPRD agonists such as beta-alanine suppress mast cell degranulation and inflammation across urticaria, mastocytosis, and related conditions.

Specific antibodies against monomeric and dimeric HRF inhibit cytokine-like activity for HRF-related diagnosis and treatment.

A solubilizer-based aqueous injectable keeps COX-2 inhibitors clear and stable, enabling ready-to-infuse parenteral delivery.

A protease-cleavable masking moiety keeps anti-EGFR antibodies inactive in circulation, then restores binding at treatment sites to limit toxicity.

Sugar-modified stem cell exosomes target activated macrophages to improve autoimmune inflammation treatment while reducing side effects.

MSC exosomes target synovial inflammation in osteoarthritis to reduce pain while supporting cartilage repair through scaffold, hydrogel, or injection delivery.

Specific CDR sequence changes improve FCRL1 selective binding, enabling more effective antibody-drug conjugates and diagnostics.

Hydrophobic chromatography separates intact activatable antibodies from clipped variants to reduce aggregation and off-target binding.

CD1a-targeting antibodies block ligand binding and induce CD1a-expressing cell death to reduce inflammatory skin, mucosal, and systemic disease.

Targeting the TL1A-DR3 pathway helps curb TH17 differentiation and IL-17, IL-22, and IL-9 release in chronic inflammatory disease.

A defined Crystal Form I uses controlled solvent-antisolvent crystallization to improve stability, solubility, and bioavailability for drug formulation.

High-affinity anti-GM-CSF antibodies use CDR sequence optimization to block GM-CSF signaling and suppress inflammatory cytokine responses.

Lentiviral SLFN11 overexpression helps expanded mesenchymal stem cells resist senescence, limit DNA damage, and improve ulcerative colitis therapy.

Supercritical CO2 and ethanol extraction raise Nigella sativa bioactive yield while improving industrial viability for thymohydroquinone-rich formulations.

Targeting IL1RAP with high-affinity antibodies blocks IL-1, IL-33, and IL-36 signaling to treat inflammatory, autoimmune, and proliferative disease.

High-concentration doxycycline injected into the subcuticular space reduces lower eyelid festoons and malar edema by preventing fluid buildup.

By binding the shared IL1RAP co-receptor, these antibodies suppress IL-1, IL-33, and IL-36 signaling across inflammatory and autoimmune disease pathways.

Autologous blood-derived extracellular vesicles are used to relieve osteoarthritis and rheumatoid arthritis pain while supporting joint repair.

Controlled headspace oxygen plus methionine, histidine, trehalose, and polysorbate 80 keep ready-to-use IL-17 antibody liquids stable.

Controlled low-oxygen headspace with methionine and stabilizers helps IL-17 antibody liquids resist oxidation and aggregation during storage.

By binding the shared IL1RAP co-receptor, one antibody blocks IL-1, IL-33, and IL-36 signaling to simplify broad pathway inhibition.

Novel TL1A-binding antibody domains block apoptosis, NFkB signaling, and cytokine secretion to improve treatment of TL1A-associated diseases.